Rhopressa safety data consistent at 6 months in Rocket 4

In the phase 3 Rocket 4 trial, Rhopressa at 6 months showed consistent safety data with previous phase 3 clinical trials of Rhopressa and remained within the non-inferiority range compared with timolol, according to Aerie Pharmaceuticals.The trial included 708 patients with open-angle glaucoma or ocular hypertension across 52 sites in the U.S., randomized 1:1 to receive either once-daily Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie Pharmaceuticals) or twice-daily timolol for 6 months, Vicente Anido Jr., PhD, chairman and CEO of Aerie, said during a conference call about the study results.

Full Story →